6.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.28
Aprire:
$6.27
Volume 24 ore:
16,815
Relative Volume:
0.43
Capitalizzazione di mercato:
$87.82M
Reddito:
$49.98M
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-8.9437
EPS:
-0.71
Flusso di cassa netto:
$-4.86M
1 W Prestazione:
+2.09%
1M Prestazione:
-23.59%
6M Prestazione:
+41.11%
1 anno Prestazione:
+34.25%
Champions Oncology Inc Stock (CSBR) Company Profile
Nome
Champions Oncology Inc
Settore
Industria
Telefono
410-369-0365
Indirizzo
855 N. WOLFE STREET, BALTIMORE, NJ
Confronta CSBR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CSBR
Champions Oncology Inc
|
6.35 | 86.00M | 49.98M | -9.64M | -4.86M | -0.71 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-09-12 | Aggiornamento | Craig Hallum | Hold → Buy |
2019-11-18 | Iniziato | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Borsa (CSBR) Ultime notizie
Sixth Annual Champions Gala Raises Money for Lehigh Valley Topper Cancer Institute - Lehigh Valley Health Network
Heartland Oncology and Hematology Oncologist Named 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO) - Seeking Alpha
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - ACCESS Newswire
Where are the Opportunities in (CSBR) - news.stocktradersdaily.com
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies - marketscreener.com
CSBR Secures License for Radioactive Material Use in Preclinical Studies | CSBR Stock News - GuruFocus
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House - Bellingham Herald
Press Release Distribution & PR Platform - ACCESS Newswire
Champions Oncology Unlocks Next-Gen Cancer Treatment Capabilities with Strategic Radiotherapy License - Stock Titan
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.9 Million - ACCESS Newswire
Champions Oncology Reports Quarterly Revenue of $12.0 Million - ACCESS Newswire
Champions Oncology (CSBR) Partners with Turbine to Boost Drug Di - GuruFocus
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine - Stock Titan
Turbine Launches the World’s First Virtual Lab Using Cell Simulations - Business Wire
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets - The Malaysian Reserve
Humanized Mouse and Rat Model Market worth US$409.8 million in 2030 with 8.2% CAGR | MarketsandMarkets™ - PR Newswire UK
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year - Yahoo
I-Apollo Hospitals, yethula i-“Cancer Champions United” isinyathelo esiyingqayizivele sokunikeza amandla Abasinde Ngomdlavuza! - Apollo Hospitals
Patient Derived Xenograft Model Market Future Business - openPR.com
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 - ACCESS Newswire
Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding - simplywall.st
American Battery Technology boosts recycled battery output - Investing.com
Apollo Hospitals, yakhazikitsa "Cancer Champions United" njira yapadera yopatsa mphamvu Opulumuka Khansa! - Apollo Hospitals
How To Trade (CSBR) - news.stocktradersdaily.com
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) - Yahoo Finance
Champions Oncology target raised to $12 at Craig-Hallum By Investing.com - Investing.com Canada
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - MSN
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Champions Oncology Achieves Record Revenue and Profit - TipRanks
Champions Oncology earnings beat by $0.37, revenue topped estimates - Investing.com Canada
Earnings call transcript: Champions Oncology Q1 2025 earnings beat expectations - Investing.com
CHAMPIONS ONCOLOGY Earnings Results: $CSBR Reports Quarterly Earnings - Nasdaq
Champions Oncology stock surges as earnings beat expectations By Investing.com - Investing.com South Africa
Champions Oncology stock surges as earnings beat expectations - Investing.com India
Champions Oncology Reports Record Quarterly Revenue and Net Income - TradingView
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million - ACCESS Newswire
Stock Index Futures Gain After Yesterday’s Selloff, U.S. JOLTs Report in Focus - TradingView
Earnings Scheduled For March 11, 2025 - Benzinga
Champions Oncology Inc Azioni (CSBR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):